Q3 2017 Earnings Estimate for Karyopharm Therapeutics Inc. Issued By Leerink Swann (NASDAQ:KPTI)
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – Equities research analysts at Leerink Swann cut their Q3 2017 EPS estimates for shares of Karyopharm Therapeutics in a report released on Tuesday. Leerink Swann analyst M. Schmidt now forecasts that the company will post earnings of ($0.64) per share for the quarter, down from their previous estimate of ($0.63). Leerink Swann also issued estimates for Karyopharm Therapeutics’ Q4 2017 earnings at ($0.64) EPS, FY2017 earnings at ($2.64) EPS and FY2018 earnings at ($2.88) EPS.
Other research analysts have also issued reports about the stock. Cantor Fitzgerald set a $18.00 price target on shares of Karyopharm Therapeutics and gave the company a “buy” rating in a report on Saturday, June 24th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $19.00 price target (up from $16.00) on shares of Karyopharm Therapeutics in a report on Thursday. BidaskClub raised shares of Karyopharm Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday. Zacks Investment Research lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th. Finally, Canaccord Genuity set a $18.00 price target on shares of Karyopharm Therapeutics and gave the company a “buy” rating in a report on Tuesday. Two investment analysts have rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Karyopharm Therapeutics has a consensus rating of “Buy” and an average price target of $14.56.
Shares of Karyopharm Therapeutics (KPTI) opened at 8.25 on Friday. Karyopharm Therapeutics has a one year low of $6.27 and a one year high of $14.63. The stock’s market capitalization is $388.76 million. The stock has a 50 day moving average of $9.15 and a 200-day moving average of $10.03.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Tuesday, August 8th. The company reported ($0.64) EPS for the quarter, meeting analysts’ consensus estimates of ($0.64). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 70.42%. During the same period in the previous year, the business earned ($0.84) earnings per share. The firm’s quarterly revenue was down 95.0% compared to the same quarter last year.
Hedge funds have recently modified their holdings of the stock. TIAA CREF Investment Management LLC increased its stake in shares of Karyopharm Therapeutics by 49.6% in the second quarter. TIAA CREF Investment Management LLC now owns 103,437 shares of the company’s stock valued at $936,000 after buying an additional 34,315 shares in the last quarter. Teachers Advisors LLC increased its stake in shares of Karyopharm Therapeutics by 2.6% in the second quarter. Teachers Advisors LLC now owns 431,350 shares of the company’s stock valued at $3,904,000 after buying an additional 10,787 shares in the last quarter. Alliancebernstein L.P. increased its stake in shares of Karyopharm Therapeutics by 31.9% in the second quarter. Alliancebernstein L.P. now owns 43,430 shares of the company’s stock valued at $393,000 after buying an additional 10,500 shares in the last quarter. Swiss National Bank increased its stake in shares of Karyopharm Therapeutics by 39.2% in the second quarter. Swiss National Bank now owns 56,850 shares of the company’s stock valued at $514,000 after buying an additional 16,000 shares in the last quarter. Finally, State of Wisconsin Investment Board purchased a new stake in shares of Karyopharm Therapeutics during the second quarter valued at $235,000. Hedge funds and other institutional investors own 57.46% of the company’s stock.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.